Vedolizumab (proposed trade name Entyvio), was developed as a treatment for patients with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD), who have failed at least one conventional therapy, including tumor necrosis factor (TNF) antagonists. Dr. Edward Loftus, M.D., reviews a recent study published in the journal Gut, in which researchers reported on the safety profile of vedolizumab.
What is already known on this subject?
What are the new findings?
Although a favourable benefit-risk profile makes vedolizumab a useful option for the long-term treatment of IBD, researchers still need to better understand and observe how its safety profile evolves over time.
Read the full study online here.
For more information about IBD, visit mayoclinic.org/IBD.
Dr. Loftus is a gastroenterologist at Mayo Clinic.